CELL INTELLIGENCE · 肿瘤细胞治疗研究

对关于“持续性细胞因子释放综合征与复发/难治性淋巴瘤成人患者接受 CD19 靶向 CAR-T 细胞治疗后低纤维蛋白原血症相关”一文的来信的回复

Response to the Letter regarding "Prolonged Cytokine Release Syndrome is Associated with Hypofibrinogenemia after CD19-Directed CAR T-Cell Therapy in

儿童慢性活动性 EB 病毒感染按优势感染淋巴细胞亚群管理后的长期结局

Long-term outcomes of chronic active Epstein-Barr virus infection in childhood after dominantly infected lymphocyte subpopulation management.

EBV 感染淋巴细胞谱分析指导 CAEBV 的长期无 HCT 控制。CD4+T 细胞型 CAEBV 需及时而非择期进行 HCT，以防疾病进展和转化。

更正：抗 CD19 CAR-T 细胞治疗日本高级别 B 细胞淋巴瘤的有效性：单中心分析

Correction: Effectiveness of anti-CD19 CAR T-cell therapy for high-grade B-cell lymphoma in Japan: a single-institution analysis.

AML/MDS 细胞治疗的最新进展

Recent advances in cell therapy for AML/MDS.

弥漫大 B 细胞淋巴瘤 axicabtagene ciloleucel 治疗后持续性帕金森综合征伴多巴胺能去神经支配：一例病例报告

Persistent parkinsonism with dopaminergic denervation following axicabtagene ciloleucel therapy for diffuse large B cell lymphoma: a case report.

抗 CD19 CAR-T 细胞治疗日本高级别 B 细胞淋巴瘤的疗效：单中心分析

Effectiveness of anti-CD19 CAR T-cell therapy for high-grade B-cell lymphoma in Japan: a single-institution analysis.

CAR-T 细胞疗法在 R/R HGBCL 患者中的疗效仍不理想。高级别形态学可能有助于识别 CAR-T 细胞治疗后预后特别差的高风险患者。

体重指数与 CD19CAR-T 细胞治疗复发/难治性 B 细胞淋巴瘤后结局：一项全国性注册研究

Body Mass Index and Outcomes after CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma: A Nationwide Registry Study.

大 B 细胞淋巴瘤 CAR-T 细胞治疗时间改善的驱动因素：一项日本全国注册分析

Drivers of temporal improvement in CAR T-cell therapy for large B-cell lymphoma: a Japanese nationwide registry analysis.

新诊断弥漫大 B 细胞淋巴瘤的新兴治疗策略

Emerging treatment strategies for newly diagnosed diffuse large B-cell lymphoma.

成人复发/难治性淋巴瘤患者中持续性细胞因子释放综合征与 CD19 靶向 CAR-T 细胞治疗后低纤维蛋白原血症的关联

Prolonged Cytokine Release Syndrome is Associated with Hypofibrinogenemia after CD19-Directed CAR T-Cell Therapy in Adult Patients with Relapsed/Refra